Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Dirix

Showing results (151-160 of 195) with videos related to

Pageof 20
Sort By:
Cancer Letters|December 3, 2014
Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancerDieter J E Peeters, Anja Brouwer, Gert G Van den Eynden, et al.
British Journal of Cancer|April 1, 2004
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxiaF Stessels, G Van den Eynden, I Van der Auwera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerHarold J Burstein, Yan Sun, Luc Y Dirix, et al.
British Journal of Cancer|April 7, 2011
Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancerD J E Peeters, G G Van den Eynden, P-J van Dam, et al.
British Journal of Cancer|February 26, 2009
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancerX B Trinh, W A A Tjalma, P B Vermeulen, et al.
Breast Cancer Research and Treatment|March 25, 2004
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancerG G Van den Eynden, I Van der Auwera, S Van Laere, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Neoplasia (New York, N.Y.)|October 21, 2016
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary TumorNick Beije, Wendy Onstenk, Jaco Kraan, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialJohn M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Pageof 20

Showing results (151-160 of 195) with videos related to

Sort By:
Pageof 20
Cancer Letters|December 3, 2014
Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancerDieter J E Peeters, Anja Brouwer, Gert G Van den Eynden, et al.
British Journal of Cancer|April 1, 2004
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxiaF Stessels, G Van den Eynden, I Van der Auwera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerHarold J Burstein, Yan Sun, Luc Y Dirix, et al.
British Journal of Cancer|April 7, 2011
Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancerD J E Peeters, G G Van den Eynden, P-J van Dam, et al.
British Journal of Cancer|February 26, 2009
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancerX B Trinh, W A A Tjalma, P B Vermeulen, et al.
Breast Cancer Research and Treatment|March 25, 2004
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancerG G Van den Eynden, I Van der Auwera, S Van Laere, et al.
Cancer|June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.
Neoplasia (New York, N.Y.)|October 21, 2016
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary TumorNick Beije, Wendy Onstenk, Jaco Kraan, et al.
Archives of Pathology & Laboratory Medicine|December 31, 2015
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialJohn M S Bartlett, Jason Christiansen, Mark Gustavson, et al.
Pageof 20